XERS
NASDAQ · Pharmaceuticals
Xeris Biopharma Holdings Inc
$7.93
+0.57 (+7.74%)
Financial Highlights (FY 2026)
Revenue
265.69M
Net Income
503.2K
Gross Margin
85.4%
Profit Margin
0.2%
Rev Growth
+38.4%
D/E Ratio
16.10
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 85.4% | 85.4% | 57.6% | 57.6% |
| Operating Margin | 8.5% | 7.7% | 27.1% | 30.1% |
| Profit Margin | 0.2% | 0.2% | 31.4% | 30.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 265.69M | 192.04M | 186.74M | 158.16M |
| Gross Profit | 226.92M | 164.02M | 107.64M | 91.17M |
| Operating Income | 22.66M | 14.74M | 50.66M | 47.67M |
| Net Income | 503.2K | 327.4K | 58.69M | 48.77M |
| Gross Margin | 85.4% | 85.4% | 57.6% | 57.6% |
| Operating Margin | 8.5% | 7.7% | 27.1% | 30.1% |
| Profit Margin | 0.2% | 0.2% | 31.4% | 30.8% |
| Rev Growth | +38.4% | +38.4% | +1.9% | +8.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 598.16M | 598.16M | 375.14M | 369.70M |
| Total Equity | 37.16M | 37.16M | 620.44M | 584.53M |
| D/E Ratio | 16.10 | 16.10 | 0.60 | 0.63 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 32.54M | 22.34M | 67.69M | 55.43M |
| Free Cash Flow | — | — | 40.84M | 33.96M |